FDA
-
-
-
-
-
-
-
ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial
-
-
-
-
-
-
-
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
-
-
-
-
-
-
-
ADC Therapeutics to Participate in March Investor Conferences
-
-
-
-
-
-
-
ADC Therapeutics reports 89.8% response rate in lymphoma trial
-
-
-
-
-
-
-
ADC Therapeutics raises $60 million in private equity financing
-
-
-
-
-
-
-
ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025
-
-
-
-
-
-
-
ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028
-
330,707 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

